We believe that current viral vector optimization technologies fall short because they fail to address a fundamental challenge, innate cellular antiviral defenses. Viral vectors used in gene therapy and vaccine applications trigger these antiviral defenses which prevents optimal production, leading to lower yield, efficiency, and limited scalability. Virica has developed a unique approach to addressing this challenge, a platform of Viral Sensitizers (VSETM) which help reduce antiviral defenses thereby increasing yield and improving critical quality attributes.